Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab

por Wang, Bing, Wu, Chi‐Yuan, Jin, Denise, Vicini, Paolo, Roskos, Lorin
Publicado 2017

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

por Budha, Nageshwar, Wu, Chi‐Yuan, Tang, Zhiyu, Yu, Tian, Liu, Lucy, Xu, Fengyan, Gao, Yuying, Li, Ruiying, Zhang, Qiuyang, Wan, Ya, Sahasranaman, Srikumar
Publicado 2022

Immunogenicity of panitumumab in combination chemotherapy clinical trials

por Weeraratne, Dohan, Chen, Alin, Pennucci, Jason J, Wu, Chi-Yuan, Zhang, Kathy, Wright, Jacqueline, Pérez-Ruixo, Juan José, Yang, Bing-Bing, Kaliyaperumal, Arunan, Gupta, Shalini, Swanson, Steven J, Chirmule, Narendra, Starcevic, Marta
Publicado 2011

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

por Desai, Jayesh, Deva, Sanjeev, Lee, Jong Seok, Lin, Chia-Chi, Yen, Chia-Jui, Chao, Yee, Keam, Bhumsuk, Jameson, Michael, Hou, Ming-Mo, Kang, Yoon-Koo, Markman, Ben, Lu, Chang-Hsien, Rau, Kun-Ming, Lee, Kyung-Hun, Horvath, Lisa, Friedlander, Michael, Hill, Andrew, Sandhu, Shahneen, Barlow, Paula, Wu, Chi-Yuan, Zhang, Yun, Liang, Liang, Wu, John, Paton, Virginia, Millward, Michael
Publicado 2020